Develops and commercializes gastrointestinal therapies. Markets linaclotide for IBS-C and CIC under the LINZESS and CONSTELLA brands. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
The market pays 28× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 96% of them.
Analysts' average target sits 64% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price looks reasonable next to what the company earns.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
An investor who bought at the very peak is down 74% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 19 buys and 17 sells. Management buying with its own money is usually read as a good sign.
Over the last 4 years, sales fell about 8% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The growth engine is running at low revs right now. Report-card grade: 39/100.
On our five-subject report card, IRWD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IRWD does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.